Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2001 1
2002 1
2004 1
2007 2
2008 1
2011 1
2015 1
2016 2
2017 2
2018 1
2019 2
2020 1
2021 1
2022 3
2023 1
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

21 results

Results by year

Filters applied: . Clear all
Page 1
Breast Density Notification: Current UK National Practice.
Varghese J, Gohari S, Regrag F, Rizki H, Faheem M, Al Naqqash A, Johnson L, Ledwidge S, Hu J, Dickens R, Wilkinson M, Jones L, Suaris T. Varghese J, et al. Among authors: ledwidge s. Clin Breast Cancer. 2022 Jan;22(1):e101-e107. doi: 10.1016/j.clbc.2021.04.013. Epub 2021 Jun 5. Clin Breast Cancer. 2022. PMID: 34099394
Therapeutic mammaplasty is a safe and effective alternative to mastectomy with or without immediate breast reconstruction.
Potter S, Trickey A, Rattay T, O'Connell RL, Dave R, Baker E, Whisker L, Skillman J, Gardiner MD, Macmillan RD, Holcombe C; TeaM and iBRA-2 Steering Groups, the Breast Reconstruction Research Collaborative, and the Mammary Fold Academic and Research Collaborative. Potter S, et al. Br J Surg. 2020 Jun;107(7):832-844. doi: 10.1002/bjs.11468. Epub 2020 Feb 19. Br J Surg. 2020. PMID: 32073654
HER2-enriched subtype and novel molecular subgroups drive aromatase inhibitor resistance and an increased risk of relapse in early ER+/HER2+ breast cancer.
Bergamino MA, López-Knowles E, Morani G, Tovey H, Kilburn L, Schuster EF, Alataki A, Hills M, Xiao H, Holcombe C, Skene A, Robertson JF, Smith IE, Bliss JM, Dowsett M, Cheang MCU; POETIC investigators. Bergamino MA, et al. EBioMedicine. 2022 Sep;83:104205. doi: 10.1016/j.ebiom.2022.104205. Epub 2022 Aug 16. EBioMedicine. 2022. PMID: 35985932 Free PMC article.
Impact of mutational profiles on response of primary oestrogen receptor-positive breast cancers to oestrogen deprivation.
Gellert P, Segal CV, Gao Q, López-Knowles E, Martin LA, Dodson A, Li T, Miller CA, Lu C, Mardis ER, Gillman A, Morden J, Graf M, Sidhu K, Evans A, Shere M, Holcombe C, McIntosh SA, Bundred N, Skene A, Maxwell W, Robertson J, Bliss JM, Smith I, Dowsett M; POETIC Trial Management Group and Trialists. Gellert P, et al. Nat Commun. 2016 Nov 9;7:13294. doi: 10.1038/ncomms13294. Nat Commun. 2016. PMID: 27827358 Free PMC article. Clinical Trial.
Current margin practice and effect on re-excision rates following the publication of the SSO-ASTRO consensus and ABS consensus guidelines: a national prospective study of 2858 women undergoing breast-conserving therapy in the UK and Ireland.
Tang SS, Kaptanis S, Haddow JB, Mondani G, Elsberger B, Tasoulis MK, Obondo C, Johns N, Ismail W, Syed A, Kissias P, Venn M, Sundaramoorthy S, Irwin G, Sami AS, Elfadl D, Baggaley A, Remoundos DD, Langlands F, Charalampoudis P, Barber Z, Hamilton-Burke WLS, Khan A, Sirianni C, Merker LAG, Saha S, Lane RA, Chopra S, Dupré S, Manning AT, St John ER, Musbahi A, Dlamini N, McArdle CL, Wright C, Murphy JO, Aggarwal R, Dordea M, Bosch K, Egbeare D, Osman H, Tayeh S, Razi F, Iqbal J, Ledwidge SFC, Albert V, Masannat Y. Tang SS, et al. Among authors: ledwidge sfc. Eur J Cancer. 2017 Oct;84:315-324. doi: 10.1016/j.ejca.2017.07.032. Epub 2017 Aug 30. Eur J Cancer. 2017. PMID: 28865259 Free article.
21 results